GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults...
Source LinkGSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults...
Source Link
Comments